Do chemical modifications dissociate between the enzymatic and pharmacological activities of beta bungarotoxin and notexin?
We have measured enzymatic, hemolytic and anticoagulant activities, lethal potencies and effects on contractions of the phrenic nerve-diaphragm preparation, by chemically modified derivatives of beta bungarotoxin (beta BuTX) and notexin, two presynaptically acting toxins which have PLA2 activity. The following chemical modifications of beta BuTX were tested: alkylation and methylation of histidine 48, alkylation of tryptophan 19, sulfonylation of tyrosine 68, oxidation of methionines 6 and 8, semicarbazide addition under varied conditions to carboxyl groups, varied extents of carbamylation or trinitrophenylation of lysines and guanidination of all lysines with or without trinitrophenylation of the N-terminal asparagine. Only the histidine, tryptophan and tyrosine residues were modified in notexin. The results obtained were compared with those previously obtained using chemically modified derivatives of Naja nigricollis and Naja naja atra PLA2 enzymes which do not have a specific presynaptic site of action. The results with oxidized methionine and lysine-modified derivatives of beta BuTX are supportive of the suggestions of others that the N-terminal region and basic residues away from the enzymatic active region contribute towards the beta type presynaptic neurotoxicity of the PLA2 toxins. Using modified derivatives of beta BuTX and notexin, the dissociations between enzymatic activities and pharmacological properties were not as marked as previously observed with N. nigricollis and N. n. atra PLA2; nevertheless, several dissociations were noted. We conclude that, just as with non-presynaptically acting PLA2 enzymes, some pharmacological actions of presynaptically acting PLA2 toxins may occur independently of phospholipid hydrolysis.
Rosenberg
P
P
Section of Pharmacology and Toxicology, University of Connecticut, School of Pharmacy, Storrs 06268.
Ghassemi
A
A
Condrea
E
E
Dhillon
D
D
Yang
C C
CC
D000595:Amino Acid Sequence; D000818:Animals; D000925:Anticoagulants; D002038:Bungarotoxins / Q000032:analysis / Q000494:pharmacology* / Q000633:toxicity; D004546:Elapid Venoms / Q000032:analysis / Q000494:pharmacology* / Q000633:toxicity; D006168:Guinea Pigs; D006461:Hemolysis / Q000187:drug effects; D066298:In Vitro Techniques; D007928:Lethal Dose 50; D008081:Liposomes / Q000032:analysis; D051379:Mice; D008969:Molecular Sequence Data; D009498:Neurotoxins / Q000032:analysis / Q000494:pharmacology* / Q000633:toxicity; D010743:Phospholipids / Q000032:analysis; D010791:Phrenic Nerve / Q000187:drug effects; D012132:Respiratory Muscles / Q000187:drug effects
D000925:Anticoagulants; D002038:Bungarotoxins; D004546:Elapid Venoms; D008081:Liposomes; D009498:Neurotoxins; D010743:Phospholipids; C005082:notexin